Faculty

Benjamin Jacob Samelson-Jones, MD, PhD

Assistant Professor of Pediatrics (Hematology) at the Children's Hospital of Philadelphia

Department: Pediatrics

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Children's Hospital of Philadelphia
Colket Translational Research Building, Rm 5028
3501 Civic Center Blvd
Philadelphia, PA 19104

Office: 267-425-0147

Publications

Search PubMed for articles

Education:
AB (Physics )
Amherst College, 2001.
MS (Biological Sciences)
Albert Einstein College of Medicine, 2006.
PhD (Biophysics)
Albert Einstein College of Medicine, 2009.
MD
Albert Einstein College of Medicine, 2009.

Links
Search PubMed for articles
Twitter profile
Ask the Expert, Bloodstream Media
Blue Sky Profile

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O'Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA.: Real-World Outcomes of Delandistrogene Moxeparvovec Gene Therapy: Motor Outcomes and Emerging Safety Concerns. Mol Ther 15(5): S1525-0016, Oct 2025.

Lee K, DeSandre A, Samelson-Jones BJ.: An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B. J Thromb Haemost 23(8): 2688-2690, Aug 2025.

Doshi BS, Markmann CA, Novak N, Rojas SJ, Davidson R, Chau JQ, Wang W, Carrig S, Rus CM, Samelson-Jones BJ, Small JC, Bhoj VG, George LA.: Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies. Mol Ther 33(7): 3073-3085, Jul 2025.

Azhwar R, Richter CE, Griffin MS, Emly SM, Yaman M, Arruda VR, Samelson-Jones BJ, Shavit JA.: Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis. Blood Adv 9(13): 3136-3148, Jul 2025.

Hussain S, Linder G, Press CA, Vossough A, Samelson-Jones BJ.: Hypertension and encephalopathy in a pediatric patient following red blood cell transfusion. Transfusion 65(6): 1196-1202, Jun 2025.

Kaczmarek R, Samelson-Jones BJ.: The timely reporting of clinical trial results answers 1 unknown for hemophilia gene therapy: no benefit of prophylactic immunosuppression. J Thromb Haemost 23(5): 1477-1479, May 2025.

Rasko JEJ*, Samelson-Jones BJ*, George LA, Giermasz A, Ducore JM, Teitel JM, McGuinn CE, High KA, de Jong YP, Chhabra A, O'Brien A, Smith LM, Winburn I, Rupon J.: Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. N Engl J Med 392(5): 1508-1517, Apr 2025 Notes: *contributed equally to work.

Samelson-Jones BJ.: Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies? Res Pract Thromb Haemost 9(1): 102716, Mar 2025.

Siner JI, Barber-Meyer S, Samelson-Jones BJ, Mech LD, Arruda VR, Crudele JM.: Ancient origin of the furin sequence in the wolf F8 gene. Open Vet J 15(5): 3216-3222, 2025.

Samelson-Jones BJ, George LA, Doshi BS.: Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies. Blood 144(21): 2185-2197, Nov 2024.